OR WAIT null SECS
November 09, 2026
Video
Pavel Strnad, MD, discusses interim RestorAATion-2 data showing RNA editing with WVE-006 restored functional M-AAT and reduced Z-AAT in Pi*ZZ AATD.
November 07, 2026
Pavel Strnad, MD, discusses pooled phase 2 data showing fazirsiran cut liver Z-AAT burden by about 90% in AATD liver disease and why screening matters now.
November 06, 2026
Article
Pooled phase 2 data show fazirsiran 200 mg cut intrahepatic Z-AAT by about 90% vs placebo in AATD liver disease, with stable lung function through the OLE.
September 08, 2026
Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.
April 08, 2026
Q1 2026 hepatology highlights include advances in MASH, hepatitis B, gene editing for AATD, and the first approved therapy for pruritus in PBC.
March 02, 2026
Catch up on new trial readouts, trends in hepatitis B birth dose vaccination, updates in a rare hepatic disease in honor of Rare Disease Day, and more.
February 23, 2026
The FDA has granted both designations to TSRA-196, an in vivo gene editing program from Tessera Therapeutics, for the treatment of PiZZ alpha-1 antitrypsin deficiency.
February 19, 2026
Interim data from the investigator-initiated trial showed treatment with a single dose of YOLT-202 led to rapid, dose-dependent increases in AAT levels to normal range.
November 12, 2025
Strnad emphasizes the promise offered by RNA therapeutics in liver disease and what potential fazirsiran may hold for AATD liver disease in a broad spectrum of patients.
November 10, 2025
Clark reviews findings from a 3-year longitudinal study comparing VCTE to liver biopsy for staging F2/F3 fibrosis in patients with AATD liver disease.